BioSpace News Archive

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s Predicate Devices provides a favorable safety profile and substantial long-term reductions in both intraocular pressure and IOP-lowering medications.

Generated cash flow from operations of $142 million in 2018 and concluded the year with a cash and cash equivalents balance of $224 million

Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film

MARIO-3 Will Evaluate IPI-549 with Tecentriq and Abraxane® in Front-Line Triple Negative Breast Cancer and IPI-549 with Tecentriq and Avastin® in Front-Line Renal Cell Cancer

Globally recognized leader in antiviral drug discovery and development

Company Announces Expanded Data From Troriluzole Phase IIb/III Long-Term Extension Study Compared To Matched Natural History Cohort

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the fourth quarter and full year of 2018.

According to the Centers for Disease Control and Prevention (CDC), Americans use preventive healthcare at half the recommended rate.

The Society for Clinical Research Sites (SCRS) and 4G Clinical today announced 4G Clinical has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides a unique opportunity for sponsors, CROs and solution providers to engage with SCRS and its members in an impactful manner.

CAQH® has developed patent-pending artificial intelligence (AI) technology to identify incorrect healthcare provider data and improve the accuracy of directories without contacting the provider.